23:21 , Nov 9, 2017 |  BC Week In Review  |  Clinical News

Merck's sprifermin meets in Phase II for OA

Merck KGaA (Xetra:MRK) reported data from the Phase II FORWARD trial to treat osteoarthritis (OA) of the knee showing that sprifermin (AS902330) met the primary endpoint, suggesting that the candidate could be a disease-modifying treatment...
21:16 , Nov 6, 2017 |  BC Extra  |  Clinical News

Merck's sprifermin passes Phase II test in OA

Merck KGaA (Xetra:MRK) reported data from the Phase II FORWARD trial to treat osteoarthritis of the knee showing that sprifermin (AS902330) met the primary endpoint, suggesting that the candidate could be a disease-modifying treatment for...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Fibroblast growth factor 18 (FGF18) Studies in patient samples and mice suggest inhibiting FGF18 signaling could help treat ovarian cancer. In patient samples,...
07:00 , Sep 24, 2012 |  BioCentury  |  Emerging Company Profile

Arcarios: Protecting chondrocytes

Current treatments for osteoarthritis treat the symptoms and relieve pain, but do not target the cause of the disease. Arcarios B.V. has established a preclinical pipeline of compounds to slow or prevent progression of bone...
07:00 , Jul 2, 2012 |  BioCentury  |  Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc. , starting with several new hires, including a CSO...
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
08:00 , Jan 30, 2006 |  BioCentury  |  Strategy

The inside story

There is really only one thing that sustainable companies must do: make sure the pipeline is full of products that will come on the market at reasonable intervals and provide reasonable levels of revenue. Given...
08:00 , Jan 30, 2006 |  BioCentury  |  Strategy

Serono chronicles

Serono chronicles Selected events tracked against Serono's weekly stock price since the company listed on the NYSE in 2000. 1/27/00 - Exclusively licenses recombinant leukemia inhibitory factor (LIF) from Amrad (now Zenyth Therapeutics) for development...
08:00 , Nov 14, 2005 |  BioCentury  |  Strategy

Pipeline stuffers

Pipeline stuffers Pipeline stuffers Serono (SWX:SEO; SRA) has announced five drug development deals this year. Two were for Phase III compounds. In 2004, only one of eight announced deals was for a Phase III compound;...
07:00 , Sep 13, 2004 |  BC Week In Review  |  Company News

Serono SA, ZymoGenetics deal

ZGEN granted SEO access to a portfolio of genes and proteins for evaluation, screening and licensing. SEO also received rights to license up to 12 products from ZGEN's internal research projects. ZGEN will have an...